KAP Regarding Tuberculosis Among Physicians in Assiut City

April 6, 2023 updated by: Esraa Abd Elkareem Mariae Mohamed, Assiut University

Knowledge, Attitudes and Practices Regarding Tuberculosis Among Physicians in Assiut City

To Strengthen tuberculosis education and awareness among physicians in Assiut city in the framework of national tuberculosis control program.

Study Overview

Status

Not yet recruiting

Conditions

Detailed Description

Tuberculosis (TB) remains a major global health problem. According to the World Health Organization (WHO), an estimated global total of 10.6 million people fell ill with TB in 2021, equivalent to 134 cases per 100 000 populations. About 1.5 million people die from TB each year - making it the 13th leading cause of death worldwide . Until the coronavirus (COVID-19) pandemic, TB was the leading cause of death from a single infectious agent, ranking above human immunodeficiency virus (HIV). TB is present in all countries but it is highly prevalent among the low socioeconomic section of the population and marginalized sections of the community .

TB is an infectious bacterial disease caused by Mycobacterium tuberculosis (Mtb), which is transmitted between humans through the respiratory route and most commonly affects the lungs, but can damage any tissue . Only about 10 percent of individuals infected with Mtb progress to active TB disease within their lifetime; the remainder of persons infected successfully contain their infection. One of the challenges of TB is that the pathogen persists in many infected individuals in a latent state for many years and can be reactivated to cause disease. According to WHO, approximately one-quarter of the world's population is latently infected with Mtb . The risk of progression to TB disease after infection is highest soon after the initial infection and increases dramatically for persons co-infected with HIV or other immune-compromising conditions .

TB is a curable and preventable disease. TB drugs are administered in different combinations of four first-line drugs which form the core of treatment regimens in the initial treatment phase of 6-9 months. Several reasons account for the failure of TB therapy such as (i) late diagnosis, (ii) lack of timely and proper administration of effective drugs, (iii) long treatment duration, (iv) non adherence to drug regimen and (v) evolution of drug-resistant TB strains. Drug-resistant TB(DR-TB) poses a significant challenge to TB therapy and control programs .

In 2014 and 2015, all Member States of WHO and the United Nations (UN) committed to ending the TB epidemic, through their adoption of WHO's End TB Strategy and the UN Sustainable Development Goals (SDGs). The UN SDGs include ending the TB epidemic by 2030 under Goal 3. WHO's End TB Strategy aims to reduce TB deaths by 90% and cut new cases by 80% between 2015 and 2030, and ensure that no family is burdened with catastrophic health expenditure due to TB.

In Egypt TB is still a health problem, which affects the young active age group with pulmonary TB more in Lower Egypt, whereas extrapulmonary cases were more in Upper Egypt, especially in the rural community . Egypt is ranked among the mid-level incidence countries and according to a WHO estimation of the TB burden in 2019, the incidence of TB was 12 per 100 000 inhabitants . The Ministry of Health and Population (MOHP) has established the National Tuberculosis Control Program(NTP) in 1979 .

The COVID-19 pandemic has undone decades of progress in the fight against TB. Globally, the estimated number of deaths from TB increased between 2019 and 2021, reversing years of decline between 2005 and 2019. The burden of DR-TB is also estimated to have increased between 2020 and 2021, with 450 000 new cases of rifampicin-resistant TB . The most obvious and immediate impact was a large global drop in the reported number of people newly diagnosed with TB. Reductions in the reported number of people diagnosed with TB in 2020 and 2021 suggest that the number of people with undiagnosed and untreated TB has grown, resulting in an increased number of TB deaths and more community transmission of infection and increased numbers of people developing TB .

Healthcare workers (HCWs) play a fundamental role in the global fight against TB . Adequate basic knowledge about TB enables the physician to suspect and deal with a TB case, whereas insufficient knowledge will lead to either escaping suspicion or improper dealing with a TB case. The delayed proper diagnosis and management of TB will cause spreading of TB and facilitate the development of resistance to anti-TB drugs .

Worldwide, many studies found that HCWs have important knowledge gaps in relation to TB diagnosis, treatment and infection prevention and control; have some negative attitudes and stigma connected with the disease; and engage in poor practices, all of which contribute to their increased risk of infection and negative impacts on patients and the community .

In Egypt, previous studies illustrated lower basic knowledge of the studied primary health care (PHC) physicians about TB. In Gharbia Governorate , the mean of satisfactory basic knowledge was 49.6%. Similar results were detected in Menofya Governorate and in Qalyubia Governorate, where the means of satisfactory basic knowledge of the studied physicians about TB were 54.5% and 48.2% respectively. Other study in Behaira Governorate reported a mean of 63% for physicians' knowledge.

Study Type

Observational

Enrollment (Anticipated)

280

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

26 years to 40 years (Adult)

Accepts Healthy Volunteers

N/A

Sampling Method

Probability Sample

Study Population

Non specialist Physicians working and providing medical care in primary health care units and Hospitals in Assiut city.

Description

Inclusion Criteria:

  • Non specialist Physicians working and providing medical care in primary health care units and Hospitals in Assiut city.

Exclusion Criteria:

  • specialist Physicians

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
To assess knowledge, attitudes and practices (KAP) on tuberculosis among physicians working in Assiut city.
Time Frame: 3 years
questionnaire will be used to assess this outcome measure.
3 years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
To explore the factors associated with the physicians' knowledge, attitudes and practices regarding tuberculosis.
Time Frame: 3 years
questionnaire will be used to assess this outcome measure
3 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Assiut University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Anticipated)

October 1, 2023

Primary Completion (Anticipated)

October 1, 2025

Study Completion (Anticipated)

October 1, 2026

Study Registration Dates

First Submitted

March 22, 2023

First Submitted That Met QC Criteria

April 6, 2023

First Posted (Actual)

April 10, 2023

Study Record Updates

Last Update Posted (Actual)

April 10, 2023

Last Update Submitted That Met QC Criteria

April 6, 2023

Last Verified

April 1, 2023

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • KAP regarding Tuberculosis

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Tuberculosis

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Saudi Arabia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe